ConductScience.org, home

Paper324964

Adverse reactions to rifampicin in antituberculosis regimens.

Girling DJ. J Antimicrob Chemother, 1977. Cited by 128 papers, by iCite.

Cite this record

ConductScience Library. Adverse reactions to rifampicin in antituberculosis regimens. Papers, record 324964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/324964

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Adverse reactions to rifampicin in antituberculosis regimens.
PubMed
Journal
J Antimicrob Chemother
PubMed
Year
1977
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
128
iCite
Relative citation ratio, by iCite
5.35
iCite
Revised in PubMed
2019-05-09
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Girling DJD J

Source PubMed

Download CSV of authors

Topics11

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RifampinMajor topic
Tuberculosis, PulmonaryMajor topic
Acute Kidney Injury
Anemia, Hemolytic
Digestive System
Humans
Influenza, Human
Liver
Skin
Syndrome
Thrombocytopenia

Source PubMed

Download CSV of topics

Cited by37

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 128 citations.

PMIDTitleJournalYearIn PapersSource
41958720A systematic review of the outcomes of desensitization for delayed-type cutaneous adverse reactions induced by antituberculosis drugs.Asia Pac Allergy2026https://conductscience.org/library/papers/41958720PubMed
39348373Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection.PLoS One2024https://conductscience.org/library/papers/39348373PubMed
37438379Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis.Sci Rep2023https://conductscience.org/library/papers/37438379PubMed
37008589Hepatotoxicity and tuberculosis treatment outcomes in chronic liver disease.J Assoc Med Microbiol Infect Dis Can2023https://conductscience.org/library/papers/37008589PubMed
34727494Four months of rifampicin monotherapy for latent tuberculosis infection in children.Clin Exp Pediatr2022https://conductscience.org/library/papers/34727494PubMed
34206314Rifamycin W Analogues from Amycolatopsis mediterranei S699 Δrif-orf5 Strain.Biomolecules2021https://conductscience.org/library/papers/34206314PubMed
328873718-Deoxy-Rifamycin Derivatives from Amycolatopsis mediterranei S699 ΔrifT Strain.Biomolecules2020https://conductscience.org/library/papers/32887371PubMed
31145192Drug hypersensitivity in HIV infection.Curr Opin Allergy Clin Immunol2019https://conductscience.org/library/papers/31145192PubMed
30567221Rifampicin: not always an innocent drug.BMJ Case Rep2018https://conductscience.org/library/papers/30567221PubMed
29996783Toxicity associated with tuberculosis chemotherapy in the REMoxTB study.BMC Infect Dis2018https://conductscience.org/library/papers/29996783PubMed
28671602Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice.Int J Mol Sci2017https://conductscience.org/library/papers/28671602PubMed
28409555Treatment of Latent Tuberculosis Infection.Microbiol Spectr2017https://conductscience.org/library/papers/28409555PubMed
27610165Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial.Iran J Pharm Res2016https://conductscience.org/library/papers/27610165PubMed
27567500Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial.BMC Infect Dis2016https://conductscience.org/library/papers/27567500PubMed
27516382Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.Clin Infect Dis2016https://conductscience.org/library/papers/27516382PubMed
26106962Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment.Clinics (Sao Paulo)2015https://conductscience.org/library/papers/26106962PubMed
25904367
Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study.
Clin Infect Dis2015https://conductscience.org/library/papers/25904367PubMed
24175948Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy.World Allergy Organ J2013https://conductscience.org/library/papers/24175948PubMed
20808293Hepatotoxic effects of therapies for tuberculosis.Nat Rev Gastroenterol Hepatol2010https://conductscience.org/library/papers/20808293PubMed
20546189Current development and future prospects in chemotherapy of tuberculosis.Respirology2010https://conductscience.org/library/papers/20546189PubMed

See all 37 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/324964

GET https://conductscience.org/api/papers/v1/324964/cited_by?page=2